Cargando…

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice

Background: The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented in prospective trials. We aim to confirm the benefits and indicate predictive factors for immunotherapy in daily practice. Methods: This study was a retrospective analysis. The median PFS and OS were...

Descripción completa

Detalles Bibliográficos
Autores principales: Knetki-Wróblewska, Magdalena, Tabor, Sylwia, Piórek, Aleksandra, Płużański, Adam, Winiarczyk, Kinga, Zaborowska-Szmit, Magdalena, Zajda, Katarzyna, Kowalski, Dariusz M., Krzakowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053214/
https://www.ncbi.nlm.nih.gov/pubmed/36983409
http://dx.doi.org/10.3390/jcm12062409
_version_ 1785015359686836224
author Knetki-Wróblewska, Magdalena
Tabor, Sylwia
Piórek, Aleksandra
Płużański, Adam
Winiarczyk, Kinga
Zaborowska-Szmit, Magdalena
Zajda, Katarzyna
Kowalski, Dariusz M.
Krzakowski, Maciej
author_facet Knetki-Wróblewska, Magdalena
Tabor, Sylwia
Piórek, Aleksandra
Płużański, Adam
Winiarczyk, Kinga
Zaborowska-Szmit, Magdalena
Zajda, Katarzyna
Kowalski, Dariusz M.
Krzakowski, Maciej
author_sort Knetki-Wróblewska, Magdalena
collection PubMed
description Background: The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented in prospective trials. We aim to confirm the benefits and indicate predictive factors for immunotherapy in daily practice. Methods: This study was a retrospective analysis. The median PFS and OS were estimated using the Kaplan-Meier method. The log-rank test was used for comparisons. Multivariate analyses were performed using the Cox regression method. Results: A total of 260 patients (ECOG 0-1) with advanced NSCLC (CS III-IV) were eligible to receive nivolumab or atezolizumab as second-line treatment. Median PFS and OS were three months (95% confidence interval [CI] 2.57–3.42) and 10 months (95% CI 8.03–11.96), respectively, for the overall population. The median OS for the atezolizumab arm was eight months (95% CI 5.89–10.1), while for the nivolumab group, it was 14 months (95% CI 10.02–17.97) (p = 0.018). The sum of all measurable changes >100.5 mm (p = 0.007; HR = 1.003, 95% CI 1.001–1.005), PLT > 281.5 G/l (p < 0.001; HR = 1.003, 95% CI 1.001–1.003) and bone metastases (p < 0.004; HR = 1.58, 95% CI 1.04–2.38) were independent negative prognostic factors for OS in multivariate analysis. Based on preliminary analyses, a prognostic index was constructed to obtain three prognostic groups. Median OS in the subgroups was 16 months (95% CI 13.3–18.7), seven months (95% CI 4.83–9.17) and four months (95% CI 2.88–5.13), respectively (p < 0.001). Conclusions: Nivolumab and atezolizumab provided clinical benefit in real life. Clinical and laboratory factors may help to identify subgroups likely to benefit. The use of prognostic indices may be valuable in clinical practice.
format Online
Article
Text
id pubmed-10053214
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100532142023-03-30 Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice Knetki-Wróblewska, Magdalena Tabor, Sylwia Piórek, Aleksandra Płużański, Adam Winiarczyk, Kinga Zaborowska-Szmit, Magdalena Zajda, Katarzyna Kowalski, Dariusz M. Krzakowski, Maciej J Clin Med Article Background: The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented in prospective trials. We aim to confirm the benefits and indicate predictive factors for immunotherapy in daily practice. Methods: This study was a retrospective analysis. The median PFS and OS were estimated using the Kaplan-Meier method. The log-rank test was used for comparisons. Multivariate analyses were performed using the Cox regression method. Results: A total of 260 patients (ECOG 0-1) with advanced NSCLC (CS III-IV) were eligible to receive nivolumab or atezolizumab as second-line treatment. Median PFS and OS were three months (95% confidence interval [CI] 2.57–3.42) and 10 months (95% CI 8.03–11.96), respectively, for the overall population. The median OS for the atezolizumab arm was eight months (95% CI 5.89–10.1), while for the nivolumab group, it was 14 months (95% CI 10.02–17.97) (p = 0.018). The sum of all measurable changes >100.5 mm (p = 0.007; HR = 1.003, 95% CI 1.001–1.005), PLT > 281.5 G/l (p < 0.001; HR = 1.003, 95% CI 1.001–1.003) and bone metastases (p < 0.004; HR = 1.58, 95% CI 1.04–2.38) were independent negative prognostic factors for OS in multivariate analysis. Based on preliminary analyses, a prognostic index was constructed to obtain three prognostic groups. Median OS in the subgroups was 16 months (95% CI 13.3–18.7), seven months (95% CI 4.83–9.17) and four months (95% CI 2.88–5.13), respectively (p < 0.001). Conclusions: Nivolumab and atezolizumab provided clinical benefit in real life. Clinical and laboratory factors may help to identify subgroups likely to benefit. The use of prognostic indices may be valuable in clinical practice. MDPI 2023-03-21 /pmc/articles/PMC10053214/ /pubmed/36983409 http://dx.doi.org/10.3390/jcm12062409 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Knetki-Wróblewska, Magdalena
Tabor, Sylwia
Piórek, Aleksandra
Płużański, Adam
Winiarczyk, Kinga
Zaborowska-Szmit, Magdalena
Zajda, Katarzyna
Kowalski, Dariusz M.
Krzakowski, Maciej
Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
title Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
title_full Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
title_fullStr Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
title_full_unstemmed Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
title_short Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
title_sort nivolumab or atezolizumab in the second-line treatment of advanced non-small cell lung cancer? a prognostic index based on data from daily practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053214/
https://www.ncbi.nlm.nih.gov/pubmed/36983409
http://dx.doi.org/10.3390/jcm12062409
work_keys_str_mv AT knetkiwroblewskamagdalena nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT taborsylwia nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT piorekaleksandra nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT płuzanskiadam nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT winiarczykkinga nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT zaborowskaszmitmagdalena nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT zajdakatarzyna nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT kowalskidariuszm nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice
AT krzakowskimaciej nivolumaboratezolizumabinthesecondlinetreatmentofadvancednonsmallcelllungcanceraprognosticindexbasedondatafromdailypractice